Pharming Group NV
PHAR16.090USD
+0.050+0.31%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Pharming Group NV Company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Pharming Group NV Info
Ticker SymbolPHAR
Company namePharming Group NV
IPO dateJul 02, 1998
CEOChouraqui (Fabrice)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
AddressDarwinweg 24
CityLEIDEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code2333 CR
Phone31715247400
Websitehttps://www.pharming.com/
Ticker SymbolPHAR
IPO dateJul 02, 1998
CEOChouraqui (Fabrice)
Company Executives of Pharming Group NV
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Ms. Barbara Yanni
Ms. Barbara Yanni
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jabine Van Der Meijs
Ms. Jabine Van Der Meijs
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ruud Van Outersterp
Mr. Ruud Van Outersterp
Chief Ethics and Compliance Officer
Chief Ethics and Compliance Officer
--
--
Dr. Richard Peters, M.D., Ph.D.
Dr. Richard Peters, M.D., Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Ms. Barbara Yanni
Ms. Barbara Yanni
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Silverberg Bernstein Capital Management, LLC
0.07%
Other
99.93%
Shareholders
Shareholders
Proportion
Silverberg Bernstein Capital Management, LLC
0.07%
Other
99.93%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.08%
Other
99.92%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
16
59.43K
0.09%
-2.30K
2025Q3
13
60.14K
0.09%
-9.65K
2025Q2
10
57.25K
0.08%
-7.99K
2025Q1
11
75.56K
0.11%
-12.14K
2024Q4
11
75.65K
0.11%
-65.36K
2024Q3
11
69.30K
0.10%
-54.56K
2024Q2
9
52.15K
0.08%
-64.69K
2024Q1
9
45.12K
0.07%
-72.64K
2023Q4
9
45.06K
0.07%
-55.56K
2023Q3
9
38.77K
0.06%
-67.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Silverberg Bernstein Capital Management, LLC
52.15K
0.08%
--
--
Sep 30, 2025
Morgan Stanley Smith Barney LLC
2.50K
0%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
2.09K
0%
--
--
Nov 30, 2025
Morgan Stanley & Co. LLC
1.81K
0%
+1.42K
+353.75%
Sep 30, 2025
EverSource Wealth Advisors, LLC
1.38K
0%
-1.60K
-53.78%
Sep 30, 2025
Mint Capital Gestora de Recursos Ltda
685.00
0%
+685.00
--
Sep 30, 2025
GWM Advisors LLC
253.00
0%
+253.00
--
Sep 30, 2025
BNP Paribas Securities Corp. North America
100.00
0%
+100.00
--
Sep 30, 2025
Global Retirement Partners, LLC
23.00
0%
+23.00
--
Sep 30, 2025
Parametric Portfolio Associates LLC
40.00
0%
+40.00
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
